Author Archives: donttradeourlivesaway

Getting cured of hepatitis C will cost you your pension

Source: Act Up Paris 28 July 2014 Sovaldi® (sofosbuvir), the new medicine against chronic hepatitis C from American laboratory Gilead, highly increases chances of recovery while also decreasing the side effects that make people stop the cure. A hope of … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, Hepatitis - C, IP Rights, patent | Leave a comment

Cost of Treatment against Hepatitis C: The French Government Must Issue a Compulsory License for Sofosbuvir and Seek the Usage of Generics

Source: Act Up Basel 28 July 2014 Act Up-Basel called the French government to learn from the current situation regarding access to new direct-acting antivirals (DAAs) molecules used in the treatment of hepatitis C (HCV), to exercise Article L613 -16 … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, Hepatitis - C, patent | Leave a comment

Gilead’s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster

Source: The New York Times 28 July 2014 Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, a huge figure that puts it on track to become one of the world’s best-selling medicines but … Continue reading

Posted in access to medicines, Drug Pricing, Hepatitis - C, Sofosbuvir | Leave a comment

Hepatitis C Pill Rockets Gilead Into Big Leagues

Source: The Wall Street Journal 28 July 2014 For decades, a liver disease that would slowly kill the infected person didn’t even have a name, let alone an effective medicine. Now, a new pill promising to cure most cases of … Continue reading

Posted in access to medicines, Drug Pricing, Hepatitis - C, patent | Leave a comment

Hepatitis C medicine being imported for Rs 1 crore

Source: Times of India 28 July 2014 MUMBAI: Even as a controversy rages on globally over the eye-popping price of US firm Gilead Science’s hepatitis C drug at $1,000 a pill, Indian patients have already begun importing the medicine from … Continue reading

Posted in access to medicines, Drug Pricing, Hepatitis - C, patent | Leave a comment

India’s role in increasing access to HCV drugs

Source: Down to Earth 28 July 2014 Early intervention by the Indian government and civil society will be essential to overcome patent barriers to ensure that the new drugs available are not priced out of reach of most people in … Continue reading

Posted in access to medicines, Drug Pricing, Hepatitis - C, HIV/Aids, Indian Patent Law, patent, Sofosbuvir, TRIPS | Leave a comment

Who can pay for hepatitis C treatment?

Source: Down to Earth 28 July 2014 On occasion of World Hepatitis Day on July 28, the World Health Organization (WHO) and its alliance partners have called on governments, civil society and people in the health sector to “think again” … Continue reading

Posted in access to medicines, Drug Pricing, Hepatitis - C, patent | Leave a comment

The drug that’s forcing America’s most important – and uncomfortable – health-care debate

Source: The Washington Post 25 July 2014 Months before Gilead Sciences’ breakthrough hepatitis C treatment hit the market, Oregon Medicaid official Tom Burns started worrying about how the state could afford to cover every enrollee infected with the disease. He … Continue reading

Posted in Drug Pricing, Hepatitis - C, patent | Leave a comment

On this World Hepatitis Day (28 July 2014), Support MSF India’s #TestnTreatHCV Campaign

Why the campaign? Hepatitis C (Hep-C or HCV) is a virus that can cause liver disease, and if untreated, can be fatal. It is a blood- borne virus that gets transmitted through unsafe injection practices; inadequate sterilization of medical equipment … Continue reading

Posted in Hepatitis - C | Leave a comment

Activists protest against Gilead at the AIDS 2014 conference in Melbourne

Posted in Drug Pricing, Hepatitis - C, patent | Leave a comment